Literature DB >> 16869758

Genotype-phenotype relationships in a mouse model for human small-cell lung cancer.

J Calbó1, R Meuwissen, E van Montfort, O van Tellingen, A Berns.   

Abstract

Lung tumors are usually classified into small-cell lung cancer (SCLC) or non-SCLC (NSCLC) depending on their pathological and histological characteristics. SCLC is defined not only by its characteristic neuroendocrine differentiation, aggressiveness, and metastatic potential, but also by a specific set of genetic aberrations, including the loss of the tumor suppressor genes p53 and Rb1 and the amplification of any member of the Myc family of oncogenes. We have previously described a mouse model of SCLC by somatic conditional disruption of Trp53 and Rb1 genes that closely resembles the human condition. Based on the possibility to study early tumor lesions and to culture and subclone progressed tumors and metastases, we discuss here a strategy to define genotype-phenotype relationships that can explain the underlying biology of lung neuroendocrine tumors. We have found that tumors may be constituted by genetically variant cell populations, which might represent different progression stages. Interestingly, we observed L-myc amplification and Ascl-1 expression in those populations showing neuroendocrine differentiation. Non-neuroendocrine cell populations from the same tumors did not show L-myc amplification nor Ascl-1 expression. We propose that this genetic divergence can play a relevant role in the definition of some phenotypic characteristics like metastasis potential or chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869758     DOI: 10.1101/sqb.2005.70.026

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  20 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

2.  Notch signaling triggers the tumor heterogeneity of small cell lung cancer.

Authors:  Lydia Meder; Reinhard Büttner; Margarete Odenthal
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.

Authors:  David G McFadden; Katerina Politi; Arjun Bhutkar; Frances K Chen; Xiaoling Song; Mono Pirun; Philip M Santiago; Caroline Kim-Kiselak; James T Platt; Emily Lee; Emily Hodges; Adam P Rosebrock; Roderick T Bronson; Nicholas D Socci; Gregory J Hannon; Tyler Jacks; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

4.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

5.  miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA).

Authors:  Guo-Long Liu; Xia Liu; Xiao-Bin Lv; Xiao-Pai Wang; Xi-Sheng Fang; Yi Sang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  Characterization of the cell of origin for small cell lung cancer.

Authors:  Kwon-Sik Park; Mei-Chih Liang; David M Raiser; Raffaella Zamponi; Rebecca R Roach; Stephen J Curtis; Zandra Walton; Bethany E Schaffer; Caitlin M Roake; Anne-Flore Zmoos; Christina Kriegel; Kwok-Kin Wong; Julien Sage; Carla F Kim
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

7.  Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

Authors:  Bethany E Schaffer; Kwon-Sik Park; Gloria Yiu; Jamie F Conklin; Chenwei Lin; Deborah L Burkhart; Anthony N Karnezis; E Alejandro Sweet-Cordero; Julien Sage
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 8.  Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology.

Authors:  Hitoshi Kitamura; Takuya Yazawa; Hanako Sato; Koji Okudela; Hiroaki Shimoyamada
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  The Mouse Tumor Biology database.

Authors:  Debra M Krupke; Dale A Begley; John P Sundberg; Carol J Bult; Janan T Eppig
Journal:  Nat Rev Cancer       Date:  2008-04-24       Impact factor: 60.716

10.  MiR-200a enhances the migrations of A549 and SK-MES-1 cells by regulating the expression of TSPAN1.

Authors:  Yaqing Chen; Wei Peng; Yixiang Lu; Jianxin Chen; York Yuanyuan Zhu; Tao Xi
Journal:  J Biosci       Date:  2013-09       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.